Search
Close this search box.

Transdermal application of H100 gel to the penile shaft in patients with Peyronie’s disease infiltrates the tunica albuginea – International Journal of Impotence Research

  • Dibenedetti D, Nguyen D, Zografos L, Ziemiecki R, Zhou X. A population-based study of Peyronie’s disease: prevalence and treatment patterns in the United States. Adv Urol. 2011;2011:282503.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Barrett-Harlow B, Wang R. Oral therapy for Peyronie’s disease, does it work? Transl Androl Urol. 2016;5:296–302.

    Article 
    PubMed 

    Google Scholar
     

  • Ziegelmann M, Savage J, Toussi A, Alom M, Yang D, Kohler T, et al. Outcomes of a novel penile traction device in men with Peyronie’s disease: a randomized, single-blind, controlled trial. J Urol. 2019;202:599–610.

    Article 
    PubMed 

    Google Scholar
     

  • Levine L, Newell M, Taylor F. Penile traction therapy for treatment of Peyronie’s disease: a single-center pilot study. J Sex Med. 2008;5:1468–73.

    Article 
    PubMed 

    Google Scholar
     

  • Martin D, Badwan K, Parker M, Mulhall J. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol. 2002;168:2483–5.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Levine L, Goldman K, Greenfield J. Experience with intraplaque injection of verapamil for Peyronie’s disease. J Urol. 2002;168:621–6.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Soh J, Kawauchi A, Kanemitsu N, Naya Y, Ochial A, Naltoh Y, et al. Nicardipine vs saline injection as treatment for Peyronie’s disease: a prospective, randomized, single-blind study. J Sex Med. 2010;7:3743–9.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Gelbard M, Goldstein I, Hellstrom W, McMahon C, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie’s disease in 2 large double-blind, randomized, placebo-controlled phase 3 studies. J Urol. 2013;190:199–207.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Twidwell J, Levine L. Topical treatment for acute phase Peyronie’s disease utilizing a new gel, H-100; a randomized, prospective, placebo-controlled pilot study. Int J Impot Res. 2016;28:41–45.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Fitch W, Easterling W, Talbert R, Bordovsky M, Mosier M. Topical verapamil HCL, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie’s disease- a placebo—controlled pilot study. J Sex Med. 2007;4:477–84.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Zemtsov A, Gaddis M, Montalvo-Lugo V. Moisturizing and cosmetic properties of emu oil: a double-blind study. Aust J Dermatol. 1996;37:159–61.

    Article 
    CAS 

    Google Scholar
     

  • Qiu X, Wang J, Fang X, Gong Z, Li Z, Yi Z. Anti-inflammatory activity and healing-promoting effects of topical application of emu oil on wound in scaled rats. Di Yi Jun Yi Da Xue Xue Bao. 2005;25:407–10.

    PubMed 

    Google Scholar
     

  • Kouoh F, Gressier B, Dine T, Luyckx M, Brunet C, Ballester L, et al. Antioxidant effects and anti-elastase activity of the calcium antagonist nicardipine on activated human and rabbit neutrophils—a potential antiatherosclerotic property of calcium antagonists? Cardiovasc Drugs Ther. 2002;16:515–20.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kinnula V, Crapo J. Superoxide dismutases in the lung and human lung diseases. Am J Respir Crit Care Med. 2003;167:1600–19.

    Article 
    PubMed 

    Google Scholar
     

  • Yamane N, Takami T, Tozuka Z, Sugiyama Y, Yamazaki A, Kumagai Y. Microdose clinical trial: quantitative determination of nicardipine and prediction of metabolites in human plasma. Drug Metab Pharmacokinet. 2009;24:389–403.

    Article 
    CAS 
    PubMed 

    Google Scholar